-+ 0.00%
-+ 0.00%
-+ 0.00%

NUVATION BIO TO EXPAND PIVOTAL PHASE 3 SIGMA STUDY OF SAFUSIDENIB FOR IDH1-MUTANT GLIOMA TO SIX EUROPEAN COUNTRIES

Reuters·10/29/2026 12:00:25

Please log in to view news